Zusammenfassung
Das Spektrum der Pharmakotherapie in der psychiatrischen Notfalltherapie wird ausführlich beschrieben. Delirante Syndrome nehmen einen breiteren Raum ein. Intoxikationen sind den spezifischen Kapiteln zugeteilt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Anderson EL, Nordstrom K, Wilson MP et al (2017) American association for emergency psychiatry task force on medical clearance of adults part I: introduction, review and evidence-based guidelines. West J Emerg Med 18(2):235–242
Asleson DR, Chiu AW (2020) Melatonin for delirium prevention in acute medically ill, and perioperative geriatric patients. Aging Med 3(2):132–137
Berek K, Grams A, Uprimny C et al (2022) Anti-NMDA receptor encephalitis and MOG-associated demyelination – a case report with long-term follow-up and a systematic review. BMC Neurol 22(1):434
Desai Boström AE, Andersson P, Rask-Andersen M et al (2023) Regional clozapine, ECT and lithium usage inversely associated with excess suicide rates in male adolescents. Nat Commun 14(1):1281
Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI) (2021) S3-Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS-Leitlinie). https://register.awmf.org/de/leitlinien/detail/001-012. Zugegriffen: 2. Juni 2023
DGPPN (Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde) (2019) S2k-Leitlinie Notfallpsychiatrie. AWMF-Register-Nr. 038-023. https://www.awmf.org/uploads/tx_szleitlinien/038-023l_S2k_Notfallpsychiatrie_2019-05_1.pdf. Zugegriffen: 2. Juni 2023
DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde e. V.), Leitliniengruppe: S3-Leitlinie Schizophrenie (Hrsg) (2019) S3-Leitlinie Schizophrenie. AWMF-Register Nr. 038-009. Langfassung. https://www.awmf.org/leitlinien/detail/ll/038-009.html. Zugegriffen: 2. Juni 2023
Katz IR, Rogers MP, Lew R et al (2022) Lithium treatment in the prevention of repeat suicide-related outcomes in veterans with major depression or bipolar disorder: a randomized clinical trial. JAMA Psychiatry 79(1):24–32
Kheirabadi D, Kheirabadi GR, Mirlohi Z et al (2020) Comparison of rapid antidepressant and antisuicidal effects of intramuscular ketamine, oral ketamine, and electroconvulsive therapy in patients with major depressive disorder: a pilot study. J Clin Psychopharmacol 40(6):588–593
Knorr R, Schöllkopf J, Haen E (2018) Das maligne neuroleptische Syndrom. Nervenarzt 89(3):300–310
Martínez-Raga J, Amore M, Di Sciascio G et al (2018) 1st international experts’ meeting on agitation: conclusions regarding the current and ideal management paradigm of agitation. Front Psychiatry 9:54
Nagel M, Freisberg S, Junghanns K et al (2015) Das maligne neuroleptische Syndrom (MNS) – Eine systematische Übersicht. Fortschr Neurol Psychiatr 83:373–380
Nishikimi M, Numaguchi A, Takahashi K et al (2018) Effect of administration of ramelteon, a melatonin receptor agonist, on the duration of stay in the ICU: a single-center randomized placebo-controlled trial. Crit Care Med 46(7):1099–1105
Ostinelli EG, Brooke-Powney MJ, Li X, Adams CE (2017) Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 7:CD9377
Pepa PA, Lee KC, Huynh HE, Wilson MP (2017) Safety of risperidone for acute agitation and alcohol intoxication in emergency department patients. J Emerg Med 53(4):530–535
Schmidt A, Fischer P, Wally B, Scharfetter J (2017) Influence of intravenous administration of the antipsychotic drug benperidol on the QT interval. neuropsychiatrie 31(4):172–175
Schönfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M et al (2020) Treatment of the neuroleptic malignant syndrome in international therapy guidelines: a comparative analysis. Pharmacopsychiatry 53(2):51–59
Stetson SR, Osser DN (2022) Psychopharmacology of agitation in acute psychotic and manic episodes. Curr Opin Psychiatry 35(3):171–176
Tebartz van Elst L, Bechter K, Prüss H et al (2019) Autoantikörper-assoziierte schizophreniforme Psychosen: Pathophysiologie, Diagnostik und Therapie. Nervenarzt 90(7):745–761
Wilson MP, Pepper D, Currier GW et al (2012) The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry project Beta Psychopharmacology Workgroup. West J Emerg Med 13(1):26–34
Yao Z, McCall WV (2023) Designing clinical trials to assess the impact of pharmacological treatment for suicidal ideation/behavior: issues and potential solutions. Pharmaceut Med 13:1–12
Zoremba N, Coburn M (2019) Delir im Krankenhaus. Dtsch Ärztebl 116:101–106
Zun LS (2018a) Evidence-based review of pharmacotherapy for acute agitation. Part 1: Onset of efficacy. J Emerg Med 54(3):364–374
Zun LS (2018b) Evidence-based review of pharmacotherapy for acute agitation. Part 2: Safety. J Emerg Med 54(4):522–532
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Müller, M.J., Benkert, O. (2023). Pharmakotherapie psychiatrischer Notfallsituationen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)